High dose of steroids not superior to low dose glucocorticoids in patients with sudden hearing loss

Germany: A recent study has shown systemic high-dose glucocorticoid therapy to be non-superior to a lower-dose regimen in patients with idiopathic sudden sensorineural hearing loss (ISSNHL) and was associated with a higher risk of side effects. 

The results, published in the journal NEJM Evidence, also raise doubts about the efficacy of the standard treatment itself. According to conservative estimates, several hundred thousand people around the world suffer from sudden hearing loss each year.

The main results of a large-scale Germany-wide randomized controlled trial with more than 300 patients led by the University Medicine Halle is that in case of sudden hearing loss, high-dose therapy with common medications is not more effective than standard treatment but is associated with a higher risk of side effects. 

Sudden hearing loss is often treated with anti-inflammatory drugs, so-called glucocorticoids, which are similar to cortisone. “There have been assumptions that a very high systemic dose of glucocorticoids administered over a short period has a superior effect compared to the standard treatment. We systematically investigated and compared the effects of different treatment strategies in the largest clinical trial with systemic glucocorticoids so far.” explains Professor Stefan Plontke, coordinating investigator of the trial and director of the Department of Otorhinolaryngology, Head and Neck Surgery at University Medicine Halle. As part of the trial, 325 patients from 39 sites across Germany were randomly assigned to three treatment groups. One group received the standard treatment, while the other two groups received a significantly higher dose of either the same drug or a similar substance. The team then looked at the extent of hearing improvement after 30 days and which side effects occurred.